Merck (MRK) Keytruda Gets EU Nod for Expanded Kidney Cancer Use

Following EU nod, Merck’s (MRK) Keytruda is now approved as an adjuvant therapy for renal cell carcinoma in certain adult patients who are at an increased risk of recurrence, following…